Across TCGA pan-cancer cohorts, LINC00686 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LINC00686 data layer compared with 10 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher LINC00686 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC00686 expression acts as an unfavorable survival marker.
SARC are the cancer types where LINC00686 Mutation most reproducibly stratifies survival.